Clinical Trial Update: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy [Phase 3]

View source ↗

Summary

This Phase 3 trial compares venetoclax plus azacitidine to azacitidine alone in newly diagnosed AML patients ineligible for standard induction therapy. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-01-27